<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969956</url>
  </required_header>
  <id_info>
    <org_study_id>TTCOD</org_study_id>
    <nct_id>NCT00969956</nct_id>
  </id_info>
  <brief_title>Time To Complications Occurs in Diabetes</brief_title>
  <official_title>Time to Complications Occurs in Diabetes. Risk Factors Determine When Diabetes Complications Occur</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes causing serious complications is well known. In this study the aim is to follow 950
      patients with diabetes for 15 years to study when, in who and how the diabetes complications
      occurs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      That diabetes cause serious diabetic complications from the eyes, kidneys, nerves and large
      vessels is known. Good metabolic control during the first 8-10 years has been shown to delay
      and even alleviate diabetes complications, but not entirely prevent them. When complications
      occur early after diabetes onset there are also likely genetic causes. If the various
      diabetes complications have different formation mechanisms or different sensitivity of blood
      sugar impact is not studied previously.

      Hypothesis:

        1. Genetic factors determine increased risk of early onset of complications.

        2. Oxidative stress increases the risk of complications.

        3. Inflammation, hyperlipidemia and hypertension leads to hypoxia and oxidative stress.

        4. Combined hypoxia and hyperglycemia leads to complications.

      Questionnaires:

        1. Are there measurable risk factors that indicate different sensitivity to develop
           diabetes complications?

        2. Are there differences between men and women?

        3. Are there differences between type 1 and type 2 diabetes?

      Knowledge achievements:

      Being able to anticipate and prevent diabetes complications with specific approaches would
      mean major benefits for patients and society.

      Inclusions criteria:

      Diabetes type 1, 2 or LADA: 18-75 years of age. Group A: 150 Type 1 Diabetes, duration 15
      years (+/- 2 years) and 150 Type 2 Diabetes 2 years (+/- 2 years) (50% K / M) Group B: 150
      Type 1 Diabetes, duration 20 years (+/- 2 years) and 150 Type 2 Diabetes 7 years (+/- 2
      years) (50% K / M) Group C: 150 Type 1 Diabetes, duration 25 years (+/- 2 years) and 150 Type
      2 Diabetes 12 years (+/- 2 years) (50% K / M) Group D: 50 LADA, onset after 35 years of age,
      duration of 5-10 years (50% K / M)

      Follow-up visits:

      Group A: After 3, 8 and 13 years Group B: After 5, 10 and 15 years Group C: After 5, 10 and
      15 years Group D: After 3, 8 and 13 years

      Definitions:

      Type 1 Diabetes: Positive ICA-antibodies and/or GAD-antibodies and/or neg C-peptide. Debut
      &lt;30 years of age.

      Type 2 Diabetes: Negative ICA-antibodies and GAD-antibodies and pos C-peptide (&gt; 0.35
      mmol/l).

      LADA: Positive ICA-antibodies and/or GAD-antibodies. Debut &gt;35 years of age.

      Retinopathy: Level of retinopathy based on fundus photography judged by experienced
      ophthalmologist and classified according to DRP classification in five steps: 1. No
      retinopathy, 2. Mild non-proliferative retinopathy, 3. Moderate non-proliferative
      retinopathy, 4. Severe non-proliferative retinopathy, 5. Proliferative retinopathy

      ESRD (end stage renal disease): Dialysis or transplantation demanding, GFR (glomerular
      filtration rate) &lt;10 ml/min.

      Overt nephropathy: Albumin excretion at least two consecutive measurements,≥ 300 mg/L and/or
      S-Creatinine &gt; 100 women and &gt; 110 mmol/l in men.

      Incipient nephropathy: Albuminuria between 30 - 300mg/L or Urine albumin/Creatinine &gt;3.

      Hypertension: Measured blood pressure in sitting position after 10 minutes rest, at least two
      consecutive measurements with at least 4 weeks in between, ≥ 130/80.

      Hyperlipidemia: ApoA-1/ApoB: &gt;0.5 and/or Triglycerides &gt;1,7 mmol/L and/or LDL &gt;2.5 mmol/L
      and/or HDL women &lt;1.3, men &lt;1.1 mmol/L and/or cholesterol &gt;4.5 mmol/L.

      Heart disease: History of myocardial infarction, angina pectoris and/or ischemic heart
      disease (file noted). Pharmacological treatment for ischemic heart disease, heart failure or
      pathological electrocardiographic changes according to Minnesota code.

      Cerebrovascular disease: Deemed to have been: if recorded in the patients file and/or if
      pathological findings demonstrated on CT/MR.

      Peripheral vascular disease: Ankle Index &lt;0.9 (blood pressure arm&gt;ankle) Clinical
      macroangiopathy, (absence of peripheral pulse) or history typical for claudication
      intermittens.

      Neuropathy: Foot investigation: According to international consensus for the investigation
      and risk assessment of diabetic feet with a view of peripheral autonomic neuropathy (PAN) and
      peripheral sensory neuropathy (PSN).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">May 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to nephropathy</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to autonomous neuropathic ulcers and Amputation</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peripheral neuropathy</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peripheral Macro-Vascular Disease, chronic Foot ulcers and Amputation</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to retinopathy</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DNA</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial markers</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Q10</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGFBP-1</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated blood pressure</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waistlines</measure>
    <time_frame>0, 3-5, 8-10 and 13-15 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Retinopathy</condition>
  <condition>Nephropathy</condition>
  <condition>Diabetic Neuropathy</condition>
  <condition>Vascular Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <description>50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Typ 1, Typ 2 and LADA Diabetics from the diabetic clinic at Sophiahemmet, Stockholm, Sweden
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes type 1, 2 or LADA: 18-75 years of age.

          -  Group A: 150 Type 1 Diabetes, duration 15 years (+/-2 years) and 150 Type 2

          -  Diabetes 2 years (+/-2 years) (50% F/M)

          -  Group B: 150 Type 1 Diabetes, duration 20 years (+/-2 years) and 150 Type 2

          -  Diabetes 7 years (+/-2 years) (50% F/M)

          -  Group C: 150 Type 1 Diabetes, duration 25 years (+/-2 years) and 150 Type 2

          -  Diabetes 12 years (+/-2 years) (50% F/M)

          -  Group D: 50 LADA, onset after 35 years of age, duration of 5-10 years (50% F/M)

          -  Type 1 Diabetes: Positive ICA antibodies and/or GAD-antibodies and/or neg C-peptide.
             Debut &lt;30 years of age.

          -  Type 2 Diabetes: Negative ICA-antibodies and GAD-antibodies and pos C-peptide (&gt;0.35
             mmol/l).

          -  LADA: Positive ICA-antibodies and/or GAD-antibodies. Debut &gt;35 years of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerstin Brismar, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Molecular Medicine and Surgery, Rolf Luft Research centre for Diabetes and Endocrinology</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004 Dec;53 Suppl 3:S39-47. Review.</citation>
    <PMID>15561920</PMID>
  </reference>
  <reference>
    <citation>Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:34-41. Review.</citation>
    <PMID>16627378</PMID>
  </reference>
  <reference>
    <citation>Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3(6):853-76. Review.</citation>
    <PMID>18200806</PMID>
  </reference>
  <reference>
    <citation>Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994 Sep;79(3):872-8.</citation>
    <PMID>7521354</PMID>
  </reference>
  <reference>
    <citation>Penckofer S, Kouba J, Wallis DE, Emanuele MA. Vitamin D and diabetes: let the sunshine in. Diabetes Educ. 2008 Nov-Dec;34(6):939-40, 942, 944 passim. doi: 10.1177/0145721708326764. Review.</citation>
    <PMID>19075078</PMID>
  </reference>
  <reference>
    <citation>Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003 May;26(5):1553-79. Review.</citation>
    <PMID>12716821</PMID>
  </reference>
  <reference>
    <citation>Kotronen A, Lewitt M, Hall K, Brismar K, Yki-Järvinen H. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab. 2008 Dec;93(12):4867-72. doi: 10.1210/jc.2008-1245. Epub 2008 Sep 16.</citation>
    <PMID>18796514</PMID>
  </reference>
  <reference>
    <citation>King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008 Aug;79(8 Suppl):1527-34. doi: 10.1902/jop.2008.080246. Review.</citation>
    <PMID>18673007</PMID>
  </reference>
  <reference>
    <citation>Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care. 2010 Feb;33(2):434-41. doi: 10.2337/dc09-1294. Review.</citation>
    <PMID>20103559</PMID>
  </reference>
  <reference>
    <citation>Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004 Mar;27(3):813-23. Review.</citation>
    <PMID>14988310</PMID>
  </reference>
  <reference>
    <citation>Gomes F, Telo DF, Souza HP, Nicolau JC, Halpern A, Serrano CV Jr. [Obesity and coronary artery disease: role of vascular inflammation]. Arq Bras Cardiol. 2010 Feb;94(2):255-61, 273-9, 260-6. Review. English, Portuguese, Spanish.</citation>
    <PMID>20428625</PMID>
  </reference>
  <reference>
    <citation>Arai Y, Kojima T, Takayama M, Hirose N. The metabolic syndrome, IGF-1, and insulin action. Mol Cell Endocrinol. 2009 Feb 5;299(1):124-8. doi: 10.1016/j.mce.2008.07.002. Epub 2008 Jul 11. Review.</citation>
    <PMID>18672019</PMID>
  </reference>
  <reference>
    <citation>Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab. 2007 Jul;9(4):483-9.</citation>
    <PMID>17587390</PMID>
  </reference>
  <reference>
    <citation>Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010 Mar 25;316(2):129-39. doi: 10.1016/j.mce.2009.08.018. Epub 2009 Aug 31. Review.</citation>
    <PMID>19723556</PMID>
  </reference>
  <reference>
    <citation>Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008 Feb;121(2):149-157.e2. doi: 10.1016/j.amjmed.2007.09.016. Review.</citation>
    <PMID>18261504</PMID>
  </reference>
  <reference>
    <citation>Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005 Apr 19;142(8):611-9.</citation>
    <PMID>15838067</PMID>
  </reference>
  <reference>
    <citation>Alagona P Jr. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care. 2009 Mar;15(3 Suppl):S65-73. Review.</citation>
    <PMID>19355805</PMID>
  </reference>
  <reference>
    <citation>Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013 Nov 11;(11):CD008143. doi: 10.1002/14651858.CD008143.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(7):CD008143.</citation>
    <PMID>24214280</PMID>
  </reference>
  <reference>
    <citation>Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014 Feb 14;(2):CD009122. doi: 10.1002/14651858.CD009122.pub2. Review.</citation>
    <PMID>24526393</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Mats Bonnier</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diabetes, Complication, Cardio-vascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

